IBM, Accelrys join hands to boost drug development
Wednesday, 20 February, 2002
IBM and software developer Accelrys have announced an alliance aimed at developing collaborative applications that will help pharmaceutical companies shorten the development cycles for new drugs.
The partnership with IBM will help Accelrys speed the release of its Discovery Studio platform, the companies said. No release date was given for Discovery Studio.
Discovery Studio is designed to shorten the drug development cycle by allowing researchers to capture and re-use scientific data that is generated by a range of sources, including Accelrys life sciences applications as well as software products developed by third parties. To help make this possible, Accelrys will incorporate support for IBM's DiscoveryLink data integration technology in Discovery Studio, the companies said.
Under terms of the four-year alliance, announced on Monday, Accelrys will use a range of high-end servers from IBM for software development, testing and knowledge management applications. As part of the alliance, IBM and Accelrys will also offer joint consulting and implementation services to deploy systems based on products from the two companies.
Relapse risk predicted for little-known autoimmune disease
Often referred to as a cousin of MS due to shared symptoms, MOGAD is a little-known autoimmune...
Perinatal HIV transmission may lead to cognitive deficits
Perinatal transmission of HIV to newborns is associated with serious cognitive deficits as...
Gene editing could make quolls resistant to cane toad toxin
Scientists from Colossal Biosciences and The University of Melbourne have introduced genetic...
